1. Home
  2. |Insights
  3. |Noncompliance with Planning "Directive" Renders Subcontract Costs Unreasonable

Noncompliance with Planning "Directive" Renders Subcontract Costs Unreasonable

Client Alert | 1 min read | 05.02.18

In the long-running case of Kellogg Brown & Root Services, Inc. (ASBCA No. 58175), the Board disallowed as unreasonable certain subcontract headcount-based dining facility costs under FAR Part 31 and the Allowable Cost and Payment clause (FAR 52.216-7(a)). The Board found KBR’s costs unreasonable because they “exceeded the amounts that should have been billed” if KBR had adjusted the subcontractor’s pricing to reflect a government-issued Letter of Technical Direction (LOTD). The LOTD told KBR to expect a lower headcount at a dining facility. KBR argued that the LOTD was issued by a government official who lacked authority to do so, and was a “planning document[], not [a] binding contract modification[],” that did not require KBR to reprice the subcontract to reflect the new anticipated headcount. The Board disagreed, finding that KBR’s disregard of a valid directive – and its failure to adjust prices to reflect the lower anticipated headcount – rendered its excess subcontract costs unreasonable (and therefore unallowable). The Board also found probative KBR’s contemporaneous treatment of the LOTD as binding and KBR’s initial issuance of a credit to the government to repay the excess dining facility costs.

Insights

Client Alert | 2 min read | 09.18.25

FDA Announces Intention to Initiate an Aggressive Enforcement Campaign Against Misleading Pharmaceutical Advertising

On September 9, 2025, the U.S. Department of Health and Human Services (HHS) and the Food and Drug Administration (HHS) issued a news release announcing an “aggressive[]” “crackdown” on direct-to-consumer pharmaceutical advertising. This release came on the heels of a Presidential Memorandum President Trump issued the same day directing HHS to “ensure transparency and accuracy in direct-to-consumer prescription drug advertisements,” and the FDA to “take action to enforce legal requirements that advertisements for prescription drugs be truthful and not misleading.”...